HomeCompareRAMMF vs JNJ

RAMMF vs JNJ: Dividend Comparison 2026

RAMMF yields 3636.36% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAMMF wins by $2866463184412.32M in total portfolio value
10 years
RAMMF
RAMMF
● Live price
3636.36%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2866463184412.34M
Annual income
$2,719,355,147,267,598,000.00
Full RAMMF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — RAMMF vs JNJ

📍 RAMMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAMMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAMMF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RAMMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAMMF
Annual income on $10K today (after 15% tax)
$309,090.91/yr
After 10yr DRIP, annual income (after tax)
$2,311,451,875,177,458,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, RAMMF beats the other by $2,311,451,875,177,457,700.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAMMF + JNJ for your $10,000?

RAMMF: 50%JNJ: 50%
100% JNJ50/50100% RAMMF
Portfolio after 10yr
$1433231592206.18M
Annual income
$1,359,677,573,633,799,400.00/yr
Blended yield
94.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RAMMF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAMMF buys
0
JNJ buys
0
No recent congressional trades found for RAMMF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAMMFJNJ
Forward yield3636.36%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$2866463184412.34M$20.0K
Annual income after 10y$2,719,355,147,267,598,000.00$827.78
Total dividends collected$2856387447109.89M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RAMMF vs JNJ ($10,000, DRIP)

YearRAMMF PortfolioRAMMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$374,336$363,636.36$10,676$355.77+$363.7KRAMMF
2$13,122,252$12,721,711.59$11,407$389.39+$13.11MRAMMF
3$430,821,997$416,781,187.80$12,198$426.53+$430.81MRAMMF
4$13,249,309,769$12,788,330,232.42$13,056$467.62+$13249.30MRAMMF
5$381,734,397,300$367,557,635,846.92$13,987$513.12+$381734.38MRAMMF
6$10,305,595,787,232$9,897,139,982,121.38$14,998$563.56+$10305595.77MRAMMF
7$260,738,028,023,917$249,711,040,531,578.75$16,098$619.52+$260738028.01MRAMMF
8$6,183,518,404,581,653$5,904,528,714,596,061.00$17,295$681.69+$6183518404.56MRAMMF
9$137,484,146,864,247,860$130,867,782,171,345,470.00$18,599$750.82+$137484146864.23MRAMMF
10$2,866,463,184,412,343,000$2,719,355,147,267,598,000.00$20,022$827.78+$2866463184412.32MRAMMF

RAMMF vs JNJ: Complete Analysis 2026

RAMMFStock

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.

Full RAMMF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this RAMMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAMMF vs SCHDRAMMF vs JEPIRAMMF vs ORAMMF vs KORAMMF vs MAINRAMMF vs ABBVRAMMF vs MRKRAMMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.